Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
18 results
D2.76 - Disease Control, Activity and Quality of Life in Chronic Spontaneous Urticaria A Cross-Sectional Study from Kazakhstan
D2.77 - Lanadelumab in C1-Esterase Inhibitor Non-Responding patient: A Case Report
D2.83 - Management of Non IgE Cow's Milk Allergy: Current Practices and Challenges
D2.75 - Prevalence of Attention Deficit Hyperactivity Disorder and Related Factors in Children Aged 6-14 Years Diagnosed with Allergic Rhinitis
D2.78 - Comparative analysis of IgE reactivity to fish extracts versus beta-parvalbumin molecules in allergic patients
D2.82 - Analytical Performance Evaluation of Cor a 8, Cor a 9, and Cor a 14 Hazelnut Components on IMMULITE 2000 XPi*
D2.84 - Avoiding Mislabeling of Drug Allergy in Patients with Recurrent Cutaneous Symptoms
D2.85 - Analytical Performance Evaluation of Bet v 4 and Cor a 1 on IMMULITE 2000 XPi*
D2.86 - Nasal Nitric Oxide in Routine Practice: Results of a One-Year Clinical Experience in Pediatric Allergology
D2.89 - Basophil Testing Beyond Positivity: Are There More Endotypes in Chronic Spontaneous Urticaria?
D3.419 - Efficacy, safety, and remission outcomes of omalizumab in elderly patients with severe allergic asthma: a subgroup analysis by age of onset
D3.420 - Real-world epidemiologic characteristics of patients treated with dupilumab for type 2 inflammatory indications: a single-center retrospective cohort study
D3.422 - Dupilumab in children with multimorbid atopic phenotype: therapy efficacy, safety and biomarker changes
D3.424 - Retrospective Analysis of Self-Administration of Biologic Treatments for Severe Asthma and Chronic Urticaria
D3.426 - Predicting response to omalizumab in patients with chronic spontaneous urticaria: The first results of the global multicenter UCARE SCOPUS project
D3.427 - Challenging the paradigm: Use of omalizumab in refractory angioedema in a 2-year-old child
D3.428 - Substratification of Biologic Treatment Using Dupilumab in Eosinophilic COPD
D3.417 - Dupilumab in pediatric patients with severe atopic dermatitis
Download the app
The congress at your fingertips
Available on
Download